Drug intelligence / Profile preview

2C-T-7

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral
01

Overview

**2C-T-7** is a synthetic psychedelic phenethylamine belonging to the "2C" family. It acts primarily as an agonist at serotonin receptors—especially the serotonin 5-HT₂A receptor—producing hallucinogenic and entactogenic effects. The compound was first described by Alexander Shulgin in his book PiHKAL. Effects typically last between eight and fifteen hours when taken orally. There is no accepted medical use for this substance; it has been associated with several fatalities and is classified as a Schedule I controlled substance in the United States due to its high potential for abuse and lack of accepted safety or therapeutic application[1][3][6]. Its mechanism of action involves serotonergic activity at central nervous system receptors implicated in hallucinogenic effects[6].

Brand names
Blue MysticTweety-Bird MescalineBeautifulTripstay7th Heaven
Other names
2,5-dimethoxy-4-(n)-propylthiophenethylamine2,5-dimethoxy-4-propylthiophenethylamine4-propylthio-2,5-dimethoxyphenethylamine4-propylsulfanyl-2,5-dimethoxyphenethylamine
02

Targets

5-HT2C (5-hydroxytryptamine receptor 2C)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on 2C-T-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2C-T-7.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call